Geode Capital Management LLC Has $143.43 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Geode Capital Management LLC boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,716,829 shares of the biopharmaceutical company's stock after purchasing an additional 8,528 shares during the period. Geode Capital Management LLC owned 1.61% of Intra-Cellular Therapies worth $143,434,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ITCI. GAMMA Investing LLC raised its stake in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Intra-Cellular Therapies in the fourth quarter worth $96,000. Wilmington Savings Fund Society FSB bought a new stake in Intra-Cellular Therapies in the third quarter worth $97,000. Barlow Wealth Partners Inc. acquired a new position in Intra-Cellular Therapies during the fourth quarter worth $184,000. Finally, R Squared Ltd bought a new position in Intra-Cellular Therapies during the fourth quarter valued at about $205,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Price Performance

ITCI stock remained flat at $131.87 during midday trading on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The business has a 50 day moving average of $130.29 and a 200-day moving average of $104.16. The company has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com started coverage on Intra-Cellular Therapies in a report on Saturday, April 5th. They set a "hold" rating on the stock. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald reissued a "neutral" rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Eleven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of "Hold" and a consensus target price of $106.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.